Monthly Archives: July 2021

Patients with inflammatory bowel disease (IBD) receive preventive care services at a lower rate than the general population. Previous research exploring preventive care services at a tertiary referral center observed that at most 75% of patients comple… Continue reading →

OP-29 is a Centers for Medicaid and Medicare Services (CMS) measure to ensure that endoscopists recommend appropriate follow-up intervals after normal colonoscopy in average risk patients. Failure to report OP-29 compliance can adversely affect hospita… Continue reading →

Careful post-procedural anticoagulation/antiplatelet (AC/AP) management is required to mitigate the risk of bleeding and/or thrombotic complications. Clearly documented recommendations for when to restart AC/AP medications after endoscopy are an essent… Continue reading →

Acute iatrogenic endoscopic perforations (AIEP) can lead to serious complications and death. If identified immediately, perforations can be closed endoscopically with a 90% success rate. Knowledge of AIEP may decrease the associated morbidity and morta… Continue reading →

Prior studies have shown low pneumococcal vaccination rates among inflammatory bowel disease (IBD) patients, yet few have assessed barriers to vaccination. In addition, minimal data exist regarding gastroenterologist (GI) and primary care provider (PCP… Continue reading →

Gastroenterology is the premiere journal in the field of gastrointestinal disease and is led by an internationally renowned board of editors. As the official journal of the AGA Institute, Gastroenterology delivers up-to-date and authoritative coverage … Continue reading →

Prompt diagnostic paracentesis upon hospital admission to evaluate for spontaneous bacterial peritonitis (SBP) has been shown to decrease mortality and length of hospitalization. Time constraints of admitting physicians and lack of training in paracent… Continue reading →

Patient-centric, orthogonal, genetic, and pharmacologic approaches identify sequential inhibition of XPO1 and ATR that may yield therapeutic benefit in TP53-mutant CRC. Continue reading →

Patients hospitalized with inflammatory bowel disease (IBD) flares are at risk of chronic steroid use when they are discharged without a clear prednisone tapering plan (and steroid-sparing treatment strategy) or gastroenterology follow-up. Our quality … Continue reading →

Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis (NASH). TVB-2640, a fatty acid synthase (FASN) inhibitor, was designed to reduce excess liver fat and directly inhibi… Continue reading →